Change search
ReferencesLink to record
Permanent link

Direct link
Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease
Show others and affiliations
Number of Authors: 15
2014 (English)In: PLOS Genetics, ISSN 1553-7390, E-ISSN 1553-7404, Vol. 10, no 12, e1004801Article in journal (Refereed) Published
Abstract [en]

Analyses of circulating metabolites in large prospective epidemiological studies could lead to improved prediction and better biological understanding of coronary heart disease (CHD). We performed a mass spectrometry-based non-targeted metabolomics study for association with incident CHD events in 1,028 individuals (131 events; 10 y. median follow-up) with validation in 1,670 individuals (282 events; 3.9 y. median follow-up). Four metabolites were replicated and independent of main cardiovascular risk factors [lysophosphatidylcholine 18∶1 (hazard ratio [HR] per standard deviation [SD] increment = 0.77, P-value<0.001), lysophosphatidylcholine 18∶2 (HR = 0.81, P-value<0.001), monoglyceride 18∶2 (MG 18∶2; HR = 1.18, P-value = 0.011) and sphingomyelin 28∶1 (HR = 0.85, P-value = 0.015)]. Together they contributed to moderate improvements in discrimination and re-classification in addition to traditional risk factors (C-statistic: 0.76 vs. 0.75; NRI: 9.2%). MG 18∶2 was associated with CHD independently of triglycerides. Lysophosphatidylcholines were negatively associated with body mass index, C-reactive protein and with less evidence of subclinical cardiovascular disease in additional 970 participants; a reverse pattern was observed for MG 18∶2. MG 18∶2 showed an enrichment (P-value = 0.002) of significant associations with CHD-associated SNPs (P-value = 1.2×10-7 for association with rs964184 in the ZNF259/APOA5 region) and a weak, but positive causal effect (odds ratio = 1.05 per SD increment in MG 18∶2, P-value = 0.05) on CHD, as suggested by Mendelian randomization analysis. In conclusion, we identified four lipid-related metabolites with evidence for clinical utility, as well as a causal role in CHD development.

Place, publisher, year, edition, pages
2014. Vol. 10, no 12, e1004801
National Category
Clinical Medicine
Research subject
Health and Welfare
URN: urn:nbn:se:du-16604DOI: 10.1371/journal.pgen.1004801ISI: 000346649900014PubMedID: 25502724OAI: diva2:775983
Available from: 2015-01-05 Created: 2015-01-05 Last updated: 2016-09-27Bibliographically approved

Open Access in DiVA

fulltext(1240 kB)42 downloads
File information
File name FULLTEXT01.pdfFile size 1240 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ärnlöv, Johan
By organisation
Medical Science
In the same journal
PLOS Genetics
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 42 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 631 hits
ReferencesLink to record
Permanent link

Direct link